← Back to Search

Cancer Vaccine

Pneumovax 23- pneumococcal polysaccharide for Type 1 Diabetes

Phase 4
Waitlist Available
Led By Ana Creo, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post vaccination
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved

Summary

This trial is testing if children with type 1 diabetes respond well to a vaccine that helps the body learn to fight off certain bacteria. Researchers want to see if these children’s immune systems work properly after getting the shot.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post vaccination for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Immunoglobulin G (IgG) Antibodies

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pneumovax 23Experimental Treatment2 Interventions
Type 1 Diabetes subjects will receive Pneumovax 23-pneumococcal polysaccharide (PPSV23)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood draw
2021
Completed Phase 4
~7380
Pneumovax 23- pneumococcal polysaccharide
2021
Completed Phase 4
~30

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,453 Total Patients Enrolled
Ana Creo, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
23 Total Patients Enrolled
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top